Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)

• Status: Completed
• Trial end date: 2007-12-01

Summary

Multinational, multicentre, randomised, prospective, open, parallel group study directly comparing two glycoprotein-IIb/IIIa inhibitors, abciximab and eptifibatide, added early to standard treatment before primary PCI of STEMI patients with respect to effect on sum-ST-resolution after 60 minutes post-procedure and other measures of myocardial reperfusion

• Phase: Phase 3

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Abciximab; Antibodies, Monoclonal; Eptifibatide; Immunoglobulin Fab Fragments